Category Archives: Pharmaceuticals

Cambridge Micelle Technology in Carocelle® Lycopene and Resveratrol anti-ageing and cardio-protective formula

Cambridge, England, 2017-Feb-14 — /EPR HEALTHCARE NEWS/ — Resveratrol and lycopene are the compounds known for anti-ageing and cardio-protective properties. Mediterranean diet based, among others, on consumption of big quantities of lycopene-rich vegetables coincides with a longer lifespan, lower incidence of CVDs and reduced occurrence of some forms of cancer among the population of Mediterranean region. High resveratrol consumption is considered a factor in “French Paradox”, where epidemiological data show low incidence of CVDs, despite high consumption of saturated fats. Consumers have enormous choice of food supplements including lycopene and resveratrol, but key information is often missing: what happens to the substance once consumed and how much of it is really absorbed?

Resveratrol – the powerful anti-ageing, antioxidant polyphenol

Resveratrol is a phytochemical from polyphenols family, compounds known for their antioxidant properties. It is produced by plants in response to different stresses from their surrounding environment and found mainly in the peel and seeds of red grapes, also in peanuts and berries. High resveratrol consumption is considered a factor in “French Paradox”, where epidemiological data show apparent disconnect between the incidence of cardiovascular diseases in French population and high consumption of saturated fats. It is thought to be related to high consumption of red wine that contains resveratrol. There is significant scientific research on the beneficial effects of resveratrol relating to anti-ageing and longevity – activation of sirtuin enzymes, support of mitochondrial metabolism, protection of telomeres, antioxidant properties. It also supports cardiovascular health and influences glucose metabolism management.

Lycopene – great contributor to healthy skin

Lycopene belongs to family of plant-derived substances – carotenoids. Due to their strong antioxidative properties carotenoids help protect plants from oxidative damage caused by various stressing factors. Scientific interest in lycopene originates from the phenomenon of the Mediterranean diet and its’ cardio-protective and longevity promoting properties. The Mediterranean diet is based, among others, on high consumption of tomatoes and other vegetables that contain high levels of lycopene and other carotenoids. The population of the Mediterranean region has a longer lifespan, lower incidence of cardiovascular diseases and lower occurrence of some forms of cancer. Because of its’ antioxidative properties lycopene helps fight against free radicals in the skin, reduces its’ sensitivity to UV radiation, reduces mitochondrial DNA damage, lowers the risk of heart diseases.

Carocelle® presents best in class lycopene and resveratrol anti-ageing supplement

The main challenge of resveratrol supplementation remains its’ bioavailability. As quickly as it is absorbed from intestinal tract to bloodstream most of it is transformed into inactive compounds. New Carocelle® Lycopene & Resveratrol formulation delivers superior bioavailability, proven in clinical trials. Carocelle® technology makes resveratrol over +500% more bioavailable than other products on the market and provides its’ outstanding concentration that would normally be difficult to obtain from other available sources.

Pharmacokinetic tests for Carocelle® Lycopene have also confirmed 2x higher concentration of lycopene in the bloodstream (bioavailability) in comparison to reference brand available on the market, with the same dosage of the compound.

Carocelle® Technology behind compounds’ superior bioavailability

Vesicle-micellisation helps carotenoids become more resistant to degradation in the highly acidic stomach environment. This ensures that more active lycopene and resveratrol can pass to the intestines and be absorbed. The vesicle-micelle format is easily transformed in the intestines by bile acids to the mixed micelles. This guarantees optimal absorption of fat-soluble ingredients, like lycopene and resveratrol. The result is increased delivery of active lycopene and resveratrol to the intestine for maximum absorption, improved bioavailability and remarkable bioactivity. Chaperone compounds in Carocelle® Lycopene & Resveratrol vesicle-micelles additionally contribute to increased bioavailability of both lycopene and resveratrol.

There are currently 3 SKUs within Carocelle® range:

Carocelle® Lycopene & Resveratrol
Carocelle® Lutein & Zeaxanthin
Carocelle® Lycopene

For more information please visit www.carocelle-technology.com or contact us at contact@carocelle-technology.com

COMPANY PROFILE
Carocelle Cambridge Micelle Technology™ was founded in 2015 in collaboration with UK biotech firm Lycotec, headed by Dr. Ivan Petyaev. The company invents proprietary formulations and products that are scientifically tested and proven in laboratories in Cambridge, UK. Carocelle Cambridge Micelle Technology™ has its headquarters in Cambridge and operates a network of partnerships with research and commercial partners around the world.

DR. IVAN MIKHAILOVICH PETYAEV, MD, PHD
Dr. Petyaev is a medical doctor, researcher and author of scientific publications and inventions with applications in diagnostics, analytics, prevention and treatment of a variety of diseases. He spent his research years at MRS and Cambridge University in the Department of Pathology. To take his discoveries into innovative healthcare products he left University and set up his own company, Lycotec Limited. Dr Petyaev has wide experience of driving his innovations through the product development phase, clinical validation and in the setting up of industrial production of the successful prototypes. His projects have been supported by Cambridge University, the MRC, Papworth and Addenbrooke’s Hospitals, the British Heart Foundation, the Department for Trade and Industry and the Eurostars Eurica Project.

Via EPR Network
More Healthcare press releases

Global leader in serialization solutions Systech to attend the annual pharmaceutical congress CPhI Worldwide in Barcelona, 4 – 6 Oct 2016

systech_international_slogo_europawireBRUSSELS, 28-Sep-2016 — /EuropaWire/ — Systech International, a global leader in brand protection technologies, will partner with Sharp Packaging and SINEL SYSTEMS, part of the Autajon Group, at CPhI Worldwide, the annual pharmaceutical congress held in Barcelona from 4 – 6 October 2016.

Systech will be part of Sharp’s panel discussion addressing delegates on the theme of “Serialization: Optimizing Your Supply Chain Means Optimizing Your Partners.” The presentation will explore the critical path to supply chain readiness, risk assessment, benchmarking and serialization risk mitigation options. The briefing will take place in the Pharma Insight Briefing room on Tuesday, 4 October 2016 at 11:30am CEST.

Systech will also showcase its UniSeries™ serialization software offered as an integrated solution within Autajon’s exhibit booth #2P16 (Hall 2).

CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, will host more than 36,000 visiting pharma professionals from 4-6 October at the Fira Gran Via, Barcelona, Spain. More than 2,500 exhibitors from 150+ countries gather at the event to network and take advantage of more than 100 free industry seminars. Every sector of the pharmaceutical market is represented under one roof, this year in a new location in Barcelona.

With thousands of implementations across the globe, Systech is the world’s most trusted brand protection expert, and its UniSeries offering is the industry standard for serializing products. UniSeries is offered as an integrated solution with both Sharp Packaging and Autajon Group’s hardware. Systech’s patented, configurable software offers manufacturers the flexibility to adapt to new regulations without extensive reworking or revalidation, thereby reducing implementation, training and support costs.

“We are recognized as the world leader in serialization and brand protection,” states Manfred Voglmaier, Senior Director Sales Europe, Systech International. “With more than 30 years of experience in providing highly configurable solutions for serialization across a variety of industries ― along with our partners Sharp Packaging and Sinel ― gives us a unique insight for this panel.”

Systech’s products are in greater demand than ever before since it is estimated that over 15,000 production lines for prescription medication in Europe must be fitted with a serialization system over the next three years. The European Commission adopted a regulation on October 2, 2015, under which the serialization of prescription medicine packages will become mandatory in all EU countries by 2019.

Show exhibit hours are on Tuesday, 4 October – Thursday, 6 October. Systech representatives will be available in the Sharp Packaging booth #3L56 (Hall 3) during the event, as well as in the Autajon booth #2P16 (Hall 2). They will showcase Systech’s software solutions on sample packaging lines and via live demos throughout the event.

SOURCE: EuropaWire

GenQual and R-Pharm collaborate to deliver predictive diagnostics for novel anti-IL-6 antibody for autoimmune diseases

Seattle, WA, San Francisco, CA and Moscow, Russia, 2016-May-25 — /EPR Healthcare News/ — R-Pharm and GenQual are pleased to announce a new collaboration focused on the development of novel predictive diagnostic tools in the area of Rheumatoid Arthritis and Autoimmune diseases.

The GenQual proprietary real-time PCR platform, when applied to the genes that are involved in the manifestation of several autoimmune diseases, allows us to detect and assess single nucleotide polymorphisms. Here, allelic determination is used as potential predictor of the treatment response by the novel anti-IL6 antibody, which is currently in development by R-Pharm.

GenQual Founder and CEO Jonathan Mirich said, “This partnership is exciting for GenQual as we advance in our goal to deliver predictive diagnostic tools for the treatment of autoimmune disorders. We are very excited about the possibilities in this space and are thankful to have quality partners in R-Pharm.”

R-Pharm CEO Vasily Ignatiev indicated the importance of the Autoimmune diseases as an area of the development and growth for R-Pharm, as well as the development of novel diagnostic tools aimed to increase the level of predictive response and efficiency of the upcoming treatment paradigm.

About GenQual
GenQual develops proprietary biomarker diagnostics for autoimmune and oncology indications.  Our personalized medicine products are designed to facilitate early disease detection and diagnosis, and to improve treatment approaches at the molecular level.  GenQual is a privately-held corporation based in Seattle, WA area, USA.

About R-Pharm
R-Pharm is a private Russian pharmaceutical company founded in 2001. It employs over 3,500 highly qualified specialists in 60+ branches. R-Pharm operates in Russia and CIS, USA, Germany, Japan, Turkey/MENA.

The company is involved in R&D, manufacturing (finished dosage forms, biotech and chemical APIs), marketing, sales and distribution of innovative pharmaceutical products in hospital/specialty care therapeutic areas.

R-Pharm collaborates with major international pharmaceutical companies and universities in the fields of drug discovery, development, clinical trials, manufacturing and commercialization.  The company operates several  GMP compliant manufacturing sites in Russia and Germany, research, BD/licensing and marketing affiliates in Japan, Germany, Turkey and US.

Marketed portfolio and pipeline features drugs used in oncology, hematology, autoimmune diseases, HIV, HCV, neurology, diabetes, cardiology, as well as antibiotics, contrast media and anesthesia agents.

Contact

R-Pharm
info@rpharm.ru
www.r-pharm.com/en/

 

GenQual

info@genqual.com
206.659.7825
www.genqual.com

 

Via EPR Network
More Healthcare press releases

Experimentica Ltd. licenses Akimba mouse model for diabetic retinopathy from Lions Eye Institute, Australia

Kuopio, Finland, December 18, 2014 — /EPR HEALTHCARE NEWS/ — The Lions Eye Institute (LEI) and Experimentica Ltd., a global ophthalmic contract research organization (CRO) announced today that they have entered into an exclusive license agreement for the Akimba mouse model for diabetic retinopathy for contract research. The license agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.

About Lions Eye Institute

The Lions Eye Institute (LEI) is the leading ophthalmic research institute in Australia. LEI employs scientists, clinicians and support staff to conduct first class scientific research into blindness and incorporates one of Australia’s largest ophthalmic practices. The Department of Molecular Ophthalmology (DMO) was founded by Professor Rakoczy in 1989 with the aim of using technological breakthroughs for the treatment of blindness. The Kimba mouse model have been successfully used in preclinical trials for a DMO developed gene therapy based treatment for wet-AMD that reached Phase I/II stage (www.lei.org.au;www.avalanchebiotech.com).

About Experimentica Ltd.

Experimentica Ltd. is a preclinical contract research organization (CRO) dedicated to develop and provide ocular disease models. Experimentica Ltd. is a global company and the largest ophthalmic CRO in Northern Europe, striving to provide scientific excellence by relying entirely on in-house expertise. Experimentica Ltd. is headquartered in Kuopio, Finland with offices in Tampere, Finland and Kansas City, MO, USA. For more information, visit www.experimentica.com.

About Bio-Link
Bio-Link Australia Pty. Ltd. is a life sciences commercialisation company which facilitates partnerships in the biopharma, medical device and diagnostic industries. Bio-Link has offices in Sydney and Melbourne, Australia, and clients including leading Australian and international biotechnology and medical device companies and medical research institutions. For more information, visit www.bio-link.com.

Contact details:
Experimentica Ltd/Giedrius Kalesnykas,
Microkatu 1, P.O.Box 1188,
70211 Kuopio, Finland.
E-mail: info@experimentica.com,
www.experimentica.com

Media enquiries:

For Experimentica:
Giedrius Kalesnykas, Ph.D.
Phone: +358 (50) 379-0275
US Toll Free: +1 (844) 393-4393
Email: gk@experimentica.com


For the Lions Eye Institute:

Francesca Robb
Communications and Media Officer
Phone: (+61 4) 09 102 556
francescarobb@lei.org.au

Via EPR Network
More Healthcare press releases

HD Biosciences, Co., Ltd. and E. J. Corey Institute of Biomedical Research Reached Agreement for Drug R&D Collaboration

HD Biosciences Co., Ltd. (HDB) and E. J. Corey Institute of Biomedical Research (CIBR) announced that they have reached a risk-sharing agreement on collaborative drug discovery and development in the therapeutic areas of infectious diseases, metabolic diseases, and oncology. This joint effort will focus on both international and Chinese markets to provide innovative medicines for unmet healthcare needs. The agreement includes lead candidate selection pre-clinical development, IND filing, clinical trials, and NDA approvals. Both companies will share financial returns from any successes or products launches.

“We are delighted to enter this partnership. The collaboration will leverage HDB’s extensive capabilities in preclinical drug discovery and development, and create long term potentials for the company.” stated Xuehai Tan, Ph.D., President & CEO of HDB. “In combination of CIBR’s expertise in drug development, we are confident to deliver novel drug candidates over the next few years, and to make this partnership a success.”

“Working with HDB gives CIBR a unique opportunity to showcase its strength in innovative drug discovery and development,” said Wuyi Meng, Ph.D., President of CIBR. “This partnership further demonstrates CIBR’s commitment in the betterment of patient’s lives by bringing forward novel medicines. We will collaborate closely with HDB to accelerate the progress of our collaborative programs”

About HD Biosciences Co., Ltd.
HD Biosciences Co., Ltd. is a Shanghai-based, biology-focused preclinical drug discovery contract research organization (CRO). The company offers comprehensive service platforms around target validation, plate-based pharmacology, hit identification and lead discovery, therapeutic antibody discovery, in vivo pharmacology, as well as other research and development services. The company currently collaborates with eight of the ten largest pharmaceutical companies in the world and has established strategic partnerships on many key R&D areas with impacts to their portfolios. The strong scientific expertise, high quality and consistency in deliveries, constantly meeting or exceeding expectations, has earned the company a great reputation in the industry, and helped the company to build its widely recognized leadership in preclinical contract research services.http://www.hdbiosciences.com

About E. J. Corey Institute of Biomedical Research
Located in the Jiangyin High-tech Industry Development Zone in Jiangyin, Jiangsu, E. J. Corey Institute of Biomedical Research (CIBR) is a non-profit research organization founded by Nobel laureate Prof. E. J. Corey with the support from Jiangyin and Jiangsu government. CIBR is committed to scientific research in the broad biomedical field and to the development of novel therapeutics to meet the unmet medical needs of patients. In addition to its strong internal research and discovery capabilities in biomedical research and drug discovery, CIBR has established solid external capabilities in translational medicine and molecular toxicology to support drug development. Under the guidance of Nobel laureate Prof. Corey, CIBR is well poised to contribute to the discovery and development of novel medicines. http://www.cibrnobel.org

Contact Details:
HD Biosciences
Ms. Jessie Yang
Email: yangxiaojie@hdbiosciences.com

CIBR
Dr. Jiaquan Wu;
Email: jwu@cibrnobel.org

 

Via EPR Network
More Healthcare press releases

HD Biosciences and Anchor Therapeutics Form Collaboration for Co-marketing Pepducin-mediated GPCR Technology

HD Biosciences Co., Ltd (HDB) and Anchor Therapeutics, Inc. today announced that they have formed a strategic collaboration to co-develop and co-market Anchor’s proprietary pepducin technology and provide novel drug development solutions to global pharmaceutical companies with drug discovery efforts focused on G-protein coupled receptors (GPCR).

Pepducins are proprietary lipidated peptide modulators for GPCR signaling. They may stabilize receptor conformation, promote or inhibit dimerization, and modulate interaction of GPCR with signalosome. As a strong research tool, pepducin technology enables high throughput screening (HTS) campaigns for the identification of special class of compounds and allosteric ligands, facilitates biophysical studies via stabilization of GPCRs in different activation states and functionally de-orphanizes GPCRs to provide tools for interrogation of pharmacology in vitro and in vivo.

As a key component of HDB’s plate-based pharmacology service capabilities, GPCR assays and screenings is one of the most active research and development areas that attracts global clients and partners in drug discoveries. With over 200 recombinant GPCR cell lines in house, some of which are orphan receptors, combining a variety assay formats with pepducin technology allows HDB to enhance its capabilities for supporting hit identification, lead discovery and receptor selectivity profiling. The collaboration is also designed to provide broader exposure and accessibility of pepducin technology across pharmaceutical and biotechnology industries through HDB’s global client base. HDB’s clients will gain unprecedented access to not only the pepducin screening platform but also HDB-Anchor’s joint expertise in GPCR research.

“Anchor’s pepducin technology has provided a novel approach to search very special GPCR related compounds that have potential to alter the receptor functions. We believe this technology will be very valuable in GPCR related drug discovery.” commented Dr. Xuehai Tan, President and Chief Executive Officer of HDB. “As one of the global leaders in biology focused contract research services, HDB emphasizes on innovative and scientific driven technologies in order to deliver extra value to our clients. The partnership between HDB and Anchor is a perfect example to demonstrate our commitment to grow the expertise and strengthen our leadership in GPCR R&D.” Dr. Tan continues his comments.

“Anchor Therapeutics is extremely pleased to partner its pepducin technology with HD Biosciences, one of the leading companies providing state of the art high throughput screening services to pharmaceutical and biotechnology clients,” said Thomas J. McMurry, PhD, Anchor’s Interim President. Dr. McMurry continued, “Through this collaboration, Anchor and HDB will expand the validation of pepducin high throughput screening probes in order to provide HDB’s clients with access to innovative screens designed to facilitate access to novel small molecule pharmacophores.”

Via EPR Network
More Healthcare press releases

Peak Nutrition’s Nourkrin Woman Provides the Answer

It isn’t just men who suffer with hair loss and their hair thinning, woman also suffer and the effects of this can have a psychological effect on all women. Peak Nutrition, providers of a range of health and well-being supplements, may have the answer with Nourkrin Woman.

As a natural food supplement, Nourkrin tablets contain only natural ingredients such as Acerola Cherry Extract, Silica Kieselguhr and Horsetail extract which means there are no side effects to worry about. There are 4 stages to taking the product that take approximately six months.

Stage 1 is the slowing and stopping of hair loss; stage 2 is the process of strengthening the existing hair; stage 3 is when it promotes the growth of dormant hair and the final process involves the strengthening of the new hair.

Andrew Skipper, Managing Director of Peak Nutrition, said:

“We know that hair thinning and hair loss can really affect a woman’s confidence so we wanted to show that there is something customers can do about it. We hope Nourkrin Woman can not only give them some hair back but their confidence and self-esteem back. Although it has a new name, it is still the same great product!”

Nourkrin is suitable for both men and women and whilst there are no guarantees in life, the product has been clinically proven to promote the growth of existing hair and stop hair loss. Peak Nutrition also has other hair loss products available such as the Hairmax Lasercomb which has proven to be extremely popular recently.

Those that have used the tablets have seen some fantastic results and if there are people out there that are suffering with hair loss, why not give Nourkrin Woman a try; you may be surprised with the results.

Peak Nutrition also has a range of other products available to buy such as Pilfood,Nanogen and Orthomol, all available at www.peak-nutrition.co.uk

Via EPR Network
More Healthcare press releases

Vital International Studies has Concluded that Aging can be Controlled

Middle aged Americans are terrified of becoming old and many say they are obsessed with coloring their gray hair. The findings of most people becoming self-conscience about aging, in spite of the old adage of “luring gray is distinguished”, are surprising findings of more than 12 months of ongoing studies, discussions and ramped up product sales of the company’s resveratrol.

In recent years, astounding results obtained in laboratories ion vertebrate and invertebrate mammals including mice and fish offer promises on many levels of health and wellness for humans. Consequently, Resveratrol has become the subject of more new scientific studies than almost any chemical compound on earth. …And for Americans, that seems to be more than suitable towards mitigating the signs of aging.

I have tried many products over the years but have never gotten the results that I am getting with your Resveratrol products!!! I have taken Vital-resV & Vital-flex as suggested -every day – two times per day for approx. 3 months.   At my recent medical checkup I got amazing results………HOORAY………THANK YOU

NICK “THE BEAR” KINZIGER

Resveratrol is a natural chemical compound found in the skin of red grapes, as well as a host of other plants and foods including mulberries, peanuts, and, of course, red wine.Resveratrol is a naturally powerful antioxidant that rids the body of free radicals. Laboratory studies have shown resveratrol protects the heart, may prevent cancer cells from forming, improves insulin sensitivity, increases the number of calories burned during exercise, and filters toxic minerals from the body.

Vital-resv.com provides consumer with the most effect form of resveratrol from its proprietary formula which includes Acai berry extract, Maqui berry extract and Grape seed extract. “The reason Vital-ResV is the most effective resveratrol, is amid the Company’s bio-enhanced technology for increased absorption”, says Chris Ingram, President at Vital International.

Vital International is working to provide consumers with a wider choice of supplements and multi-vitamin products. The Company’s Vital-ResV Resveratrol studies were comparatively mentioned on 60 minutes as featured on the Company’s website atwww.vital-resv.com.

If you’d like more information about this topic, or to schedule an interview with Chris Ingram, please call 877-500-1969 or email chris.ingram@vital-resv.com

Via EPR Network
More Healthcare press releases

Vitamin D Pharmacy’s YouTube Video Surpasses the 2000 View Mark as Winter Sets in and the Hours of Vitamin D Producing Sunshine Decrease

New Life Pharmacy in Glasgow is on a mission to raise awareness of vitamin D deficiency and in turn, reduce the number of people suffering from its related health issues.

In April 2012 Elizabeth Roddick, Fellow of the Royal Pharmaceutical Society of Great Britain, pharmacist and owner of the New Life Pharmacy released a video on YouTube that explains the health risks of being deficient in vitamin D. Low levels of this important vitamin have been linked with diabetes, arthritis, high blood pressure, hypothyroidism and cancer.

More recently, studies have found that a high level of vitamin D in women under the age of 75 can decrease the risk of macular degeneration and the loss of central vision, which is a main cause of partial-blindness in people over 50 years old (Qureshah, 2012). Vitamin D deficiency can also lead to health issues and diseases such as rickets, multiple sclerosis, depression and respiratory tract infections.

Vitamin D is produced when ultra violet (UVB) rays coming from the sun hit the skin. It is then absorbed through the liver where it is converted to calcidiol. It then works to check the calcium and phosphate levels in the blood, which are important for maintaining healthy bones. Vitamin D can also be found in some foods such as eggs, oily fish and fortified cereals.

It is common knowledge that all people’s vitamin D levels drop during the winter (November to March) as the sun is weaker during this time. A recent study (Qureshah, 2012) found that during the winter 28 percent of women had deficient levels of vitamin D, and 33 percent of women had insufficient levels. Being regarded as deficient means the level of vitamin D is less than 20ng/mL, insufficient is having 20-29ng/mL. Compare this with the summer statistics where only 5% are deficient in vitamin D and the contrast is clear.

According to Roddick, the skin needs to be exposed at the hottest time of the day (between 10am and 3pm) for about 15 minutes. These are the hours where the UVB rays are strongest and so vitamin D is most prevalent. This of course completely opposes the advice given out by skin cancer charities who urge sun bathers and holiday makers to stay out of the sun during these peak hours. Roddick does add, “It is of course very important than the skin does not burn since that can lead to skin cancer.”

Roddick believes that, “supplementation is required for most people. Also, because there are certain people who shouldn’t take vitamin D and a wide range of doses are available it can be confusing. Advice needs to be available when purchasing the products.”

Via EPR Network
More Healthcare press releases

Sprint Bioscience Strengthens Its Cancer Metabolism Portfolio

Sprint Bioscience, a Swedish company developing oncology therapeutics targeting cancer metabolism, announced today that it has raised money to strengthen its drug discovery portfolio.

The investment by Första Entreprenörsfonden and Almi Invest will enable the company to continue to build a pipeline of drug discovery projects within cancer metabolism.

“We are investing in Sprint Bioscience because we consider their entrepreneurial drive and their particular skills in drug development to be key success factors for the changing environment of the future pharmaceutical industry. Sprint Bioscience’s business strategy involves out-licensing or collaborating at an early stage of drug discovery to ensure that projects are developed with a focus on current and relevant market needs,” says Rune Nordlander, partner at Första Entreprenörsfonden.

Sprint Bioscience is a company founded by experienced drug hunters with an ambition to improve the drug discovery process. “We believe in small organisations with effective working procedures and collaborations throughout the sector,” says the company’s CEO and co-founder, Dr. Anders Åberg.

“Sprint Bioscience has developed an efficient, fragment-based drug discovery (FBDD) platform that can take parallel projects from initial idea to active molecules tested in cell-based systems in a very short time” Anders Åberg continues. Our goal is to align the early phase in the laboratory with pharmaceutical companies’ needs.

Targeting the metabolism in tumours provides exciting opportunities to develop drug therapies with novel mechanisms of action. This could be used to overcome the resistance that many cancer cells develop to current treatments.

Via EPR Network
More Healthcare press releases

Boots UK and Macmillan Cancer Support launch new role to help millions access cancer information

According to new research* almost a third of people affected by cancer felt that they had insufficient information and support outside of their healthcare team. Boots UK and Macmillan have specially trained over 500 Boots Macmillan Information Pharmacists to help improve the lives of those affected by cancer**. They will be available in many Boots stores to help connect people to information and support in their local area.

The launch of the Boots Macmillan Information Pharmacist is the first time that the role of a pharmacist has been extended to include this type of cancer information and support. It is estimated that 2 million people are currently living with or beyond cancer in the UK and this is anticipated to increase to 4 million by 2030***. As the demand for cancer health care is set to rise, the launch of this innovative pharmacy role aims to help the millions of people affected by cancer access the information and support they need, in an accessible and trusted environment.

Ciarán Devane, Chief Executive of Macmillan, commented: “The Boots Macmillan Information Pharmacists are the next stage in what is already a strong and sector-leading partnership that we both are extremely proud of. Macmillan and Boots UK believe that by sharing expertise and working together, we can reach even more of the millions of people affected by cancer than we are currently.”

The research also showed that nearly three quarters (74%) of people living with cancer felt that the information and support they received outside of their healthcare team made them better equipped to understand their cancer experience:
– 92% felt it had a positive impact on their emotional, physical or financial well being
– 51% felt able to understand more about their cancer and their experience of it
– 48% felt able to make decisions that were right for them

Alex Gourlay, Chief Executive of Health & Beauty Division, Alliance Boots, added:
“The introduction of the Boots Macmillan Information Pharmacist means that for the millions of customers that visit Boots pharmacies across the country, they can access increased cancer information and support. The findings from this research highlight just how important accessing the right information at the right time can be for people affected by cancer and the role it can play in helping them to manage their condition.”

Visit www.boots.com/cancer to find your nearest Boots Macmillan Information Pharmacist. For cancer support contact Macmillan on 0808 808 0000 or visit www.macmillan.org.uk.

Via EPR Network
More Healthcare press releases

BootsWebMD.com launches Baby Personality Quiz

BootsWebMD.com has launched a new, online Baby Personality Quiz which highlights several key traits to look out for when analysing a baby’s temperament.

With the help of the Baby Personality Quiz* on the BootsWebMD.com Children and Parenting Health Centre, users can identify their baby’s personality by answering a series of simple questions about their behaviour. The results of the quiz can then be analysed to identify their behaviour patterns. Essential information about the best approach in managing a child’s behaviour habits can also be found, with a simple step-by-step guide to keeping in sync with the baby. It could even help users to work in tandem with their child’s temperament and personality to make life easier for both parent and child.

Whether the child is feisty or easy-going, the answer to identifying its personality and behaviour patterns lies in a number of key areas. According to paediatrician Dr William Carey, author of ‘Understanding Your Child’s Temperament’, these include:

Activity/energy level – if the child has high or low energy levels, parents need to look for ways to keep them moving at a pace that’s comfortable for them Approach to newness – a naturally hesitant or shy baby will need extra reassurance and patience to overcome their shyness.

Intensity – if a baby is laid back, they can get lost in the shuffle of family life and vice versa. If the baby is intense they must be taught to deal with the curves of life

Sensitivity – if a baby has high sensitivity to lights, noise or texture, parents must be patient and look for ways to avoid sensory overload such as the lighting and the type of clothes the baby wears.

Regularity – if everything is unpredictable, potty, naps, moods, parents have to let go of their controlling ways and loosen up. Conversely, if a baby likes structure, parents might have to adhere to the schedule they crave

Persistence – puzzles are great tools to lengthen attention span, along with a daily dose of bedtime reading.

Overall mood – parents should take the time to observe their baby’s daily patterns and what makes them smile for a happier baby.

Via EPR Network
More Healthcare press releases

BootsWebMD.com Reveals New Research Into Brits’ Summer Fitness Regimes

BootsWebMD.com has revealed new research showing that Brits are going for gold as they gear up for a summer of sport. However, the research also showed that many are sustaining unnecessary workout-related injuries.

Over half of survey respondents (53%) said they have started a new fitness regime in 2012, with the main motivation among those who have done so being to keep fit rather than lose weight.

Their good intentions are making them feel less stressed (44%) and more confident (31%), yet nearly one in five (16%) has sustained an injury. As well as bruises, the most common injuries are ankle or wrist sprains (26%), shin splints (23%), pulling a muscle (23%) and hamstring injuries (19%).

Over one third (39%) from the survey of 2,000 people who said they have started a new fitness routine in 2012 look online for fitness information. In fact, among the top ten search terms on BootsWebMD.com’s fitness centre are ‘hamstrings’ and ‘shin splints’, reflecting the common injuries identified in the research.

Richard Callender, fitness instructor and TV trainer from ITV’s ‘The Biggest Loser’, said: “It’s really encouraging to see so many people getting more active in 2012. Everyone has different motivations for exercising, whether it’s to keep fit, lose weight, de-stress or just to have fun and socialise with friends and family, but it’s vital they all know how to exercise safely.”

The research shows that for people to continue this positive step, stay healthy and prepare for a summer of sport, they need to be taking greater care when exercising. Over a quarter (27%) of people surveyed admit they do not feel confident they are exercising in a correct and safe way/ Reasons for injury include not following instructions properly (28%), exercising too strenuously (34%) or not being offered proper inductions (23%). A third (33%) of the injuries has led to a long-term health problem.

Dr Rob Hicks, GP and BootsWebMD.com contributor, said: “Exercising is one of the best ways for people to stay fit and healthy, and it’s important that people look after themselves and follow the correct instructions when they exercise and know what level of exercise they should be adopting. There are both short and long-term health consequences of not exercising safely and people should ensure they feel comfortable with what they are doing before they start.”

Further findings from the research showed that more women (54%) than men (52%) have taken up a new fitness routine in 2012. The age group most likely to have started a fitness routine this year is those between 18-24 (64%).

Via EPR Network
More Healthcare press releases

Stem Cell Treatment Give CMT Patient Second Chance At Life!

“Pat receive a life altering Stem Cell Treatment with the help of World Stem Cells, LLC. Pat went from couch bound to walking 1.5 miles on country dirt road, climbing stairs, gardening and playing piano all thanks to a stem cell treatment.”

Pat is a 69-year-old woman with Charcot-Marie-Tooth disease, or CMT. She had been experiencing the effects of CMT for more than thirty years, and her progressive motor sensory neuropathy had become severe enough to interfere with every aspect of her life. She could no longer play piano, balance well enough to climb up steps or get dressed easily or summon the energy to work for more than a couple of hours before taking a rest break. Pat’s form of CMT is CMT1A, which is the most common form of this autosomal dominant condition. Her symptoms were typical of CMT; patients typically endure progressive muscle wasting and weakness in the legs, and a later loss of hand strength, balance, coordination and fine motor skills.

Pat’s neurological disorder is hereditary, and the official position of the National Institute of Neurological Disorders and Stroke is that CMT has no cure. Decades ago, Pat had gone to a neurologist for electromyography, or EMG. The purpose of the procedure was to evaluate her muscle function, and it involved painful needles and days of muscle soreness after each session. Pat’s neurologist had refused to tell her the results because he said that she would “just give up” if she knew how bad they were. At this point, Pat’s symptoms were so crippling and unbearable that she contacted World Stem Cells, LLC worldstemcells.com to explore stem cell treatment as an option. She knew that the procedures were still being developed and experimental, and that they came with no guarantees. She remained interested in learning more and becoming educated on the options presented. At the time, she was unable to walk without a four-leg quad cane, and air and car travel were exhausting and caused unbearable pain. Pat has a long history of surgeries and was told that further surgeries would not assist her. She decided that she was not interested in any treatment that involved surgery with incisions, which is an aggressive approach and would demand recovery time. Stem cell therapy met her requirements of being minimally uncomfortable, requiring only hours for recovery and having a high level of safety, along with a good potential for changing her health quotient for the better.

Pat arrived in Cancun, Mexico, to the treatment site of World Stem Cells, LLC contract clinics, doctors, and hospitals. The first day, she met with physician Dr. Sylvia M. Abblitt to be evaluated, discuss her course of treatment and learn what to expect. She had been corresponding with Dr. Alan Kadish, the President of World Stem Cells, LLC. worldstemcells.com

Dr. Kadish is an unusual physician as he has training and practiced integrated primary care medicine combining conventional and naturopathic diagnostics and therapeutics for 27 years. He has been recognized as one of the leading quality physicians, in his field. Dr. Kadish is an American Board of Anti-Aging Medicine diplomat and completed numerous training programs in Achieving Clinical Excellence, or ACE, which provided opportunities to improve his practical skills in diagnosing and treating people based on their individual needs, using functional medical testing and treatment. He has been an advanced level practitioner (Autistic Research Institute) for autistic spectral disorder children and adults, since early 2000 and is certified in chelation therapy. As a naturopathic medical physician he lecturers frequently and is a host and guest on radio and internet outlets along with appearing in a number of print media publications. At World Stem Cells , LLC in addition to his management duties, he is a primary investigator engaged in research and designs of stem cell therapeutic protocols.

In Cancun, Pat met with specialists at Advanced Cellular Medicine Clinic. The clinic is headed by Dr. Sylvia Abblitt, who has the exclusive distinction of being among the few physicians who are licensed to perform autologous and allogeneic stem cell transplants in Mexico. Dr. Abblitt is a board-certified hematologist and oncologist. She has 11 years of expertise as a laboratory director and head of the hematology department at the Fernando Quiroz Hospital. She is a member of the American Association of Blood Banks and the International Cellular Medicine Society (ICMS).

The Cancun clinic that Pat visited is a contract clinic of World Stem Cells, LLC. It houses the state-of-the-art Advanced Cellular Engineering Lab. The high-tech lab is suited for providing patients with the most up to date stem cell treatments and for conducting stem cell research to improve future opportunities for health.

After her evaluation and discussion of treatment options, Pat decided to go ahead with the stem cell therapy. The procedure involved a needle puncture to harvest her bone marrow utilizing her own stem cells. Only a local anesthesia was necessary and though she described the procedure as “uncomfortable,” she added that it was“livable.” The procedure took less than half an hour, and she experienced no side effects.

Pat’s improvement was remarkable and rapid. In fact, she did not feel fatigued and overwhelmed with pain, as she had in the past, when she traveled back home from Cancun by airplane and car. Within days, she had regained her ability to play piano. Playing at church concerts had always been a passion of hers, but she had been unable to play before her stem cell treatment because of a lack of coordination. She had much more energy after treatment, and was able to garden, run errands and work, without feeling exhausted. Her sleep was more restful. Her husband and friends noticed that her agility and balance were better. She could climb up and down stairs more easily and walk around the house without clutching the walls. Her speed on the treadmill was increasing gradually and she now walks a mile and a half on country roads.

Pat is extremely grateful to World Stem Cells, LLC for changing her life and giving her hope. For the first time, she has reversed many of the negative changes that she had been experiencing for years due to her CMT and lack of effective treatment. Now, Pat and her husband are experiencing a bright future and thankful that Pat was given this second opportunity, following stem cell therapy.

Working under the guidelines set forth by international cellular medical society (ICMS) World Stem Cells, LLC provides Stem Cell Treatment for Ankylosing Spondylitis, Autism, Cerebral Palsy, Charcot-Marie-Tooth Disease (CMT), Crohn’s Diseases, COPD, Fuch’s disease, Guillain-Barre’ Syndrome, Hashimoto’s Thryroiditis, ITP, Kidney Diseases, Macular Degeneration, Lupus (SLE), Multiple Sclerosis, PAD, Parkinson’s disease, Rheumatoid Arthritis, Scleroderma, Stroke, Ulcerative Colitis at its contract Clinics, GLP laboratory, doctors and hospitals in the beautiful resort area of Cancun. We endeavor to provide the best care possible at a mediate price while providing documentation of all treatments that can be used to provide better future care and scientific data to the medical industry.

Via EPR Network
More Healthcare press releases

‘The Economic Downturn’ Leads To £1bn Worth Of Angst

Anti-depressant and anxiety drug use has risen 26 per and cost the health service over £1billion since the start of the economic downturn in 2007, according to recent research.

A study by The Co-operative Pharmacy into antidepressant and anxiety drug dispensing across over 150 primary care trusts in England found that in 2010/11 49.8 million items were prescribed, up from 39.5 million items in 2007/08.

However, costs have fallen – down 12 percent from almost £291million in 2007/08, to£258 million in 2010/11.

In 2010/11, the North West had the highest usage of anti-depressants and anxiety medication, with over 8 million items prescribed. It was followed by East of England (5.7m) and Yorkshire and Humber (5.45m) The biggest increase in use over the last four years has been in the East Midlands up 44 percent from 3 to 4.4million items followed by the North East, up 29 percent from 2.7 to 3.5 million items.

Findings by The Co-operative Pharmacy revealed that between 2007/08 and 2010/11 the NHS has spent £1.071billion on prescribed anti-depressants and anxiety drugs. It has also funded a further £1.073billon on drugs for treating psychoses and other related disorders.

Mandeep Mudhar, NHS Business Director, The Co-operative Pharmacy, said: “Our research has shown that the NHS is getting greater value for money but worryingly prescription items have risen at an alarming rate, up 26 per cent in just four years.

“It is clear more people are seeking medical help to treat depression and anxiety. However, there are many more people who do not share their experiences. If people do feel depressed we urge them to seek medical help.”

The research found that citalopram hydrobromide was the most common anti-depressant medication (12.1million items prescribed in 2010/11) followed by amitriptyline HCl (8.8 million prescription items). 5.2 million items of fluoxetine (known commonly as Prozac) were prescribed in 2010/11.

Diazepam was the most widely prescribed drug for anxiety (1.5 million items prescribed in 2010/11).

Emer O’Neill, Chief Executive of Depression Alliance, said: “For some people depression just happens, but for others it is triggered by stressful events, for example losing a job, property or bereavement. These uncertain economic times are linked to an increase in the number of people with the illness.

“However, this is just the tip of the iceberg, as for every person diagnosed with depression there are many more who suffer in silence. Getting an early diagnosis, finding the right support mechanisms and treatment for each individual is crucial to beating the illness. At this time of year, many individuals can feel lonely or isolated but there are a range of support groups available to help with depression. Talking about your feelings is the first step to getting help whether it’s making them known to a friend or family member. It is also important to speak to a healthcare professional such as your GP or pharmacist who can help you to find the best way forward.”

Information is as follows: SHA – 2010/11 anti-depressants/anxiety items – 2007/08
anti-depressants/anxiety items – Items percentage increase/decrease – 2010/11
anti-depressants/anxiety cost – 2007/08 anti-depressants/anxiety cost – Cost
percentage increase/decrease

East Midlands – 4,413,883 – 3,058,017 – +44% – £21,834,708 – £21,334,086 – +2%
East of England – 5,754,445 – 4,550,874 – +26% – £29,602,516 – £33,056,045 – -36%
London 4,555,855 – 3,674,820 – +23% – £25,744,819 – £29,375,164 – -12%
North East – 3,518,868 – 2,725,867 – +29% – £16,660,115 – £19,764,544 – -16%
North West – 8,210,175 – 6,733,905 – +22% – £42,646,532 – £49,872,591 – -15%
South Central – 3,725,478 – 3,006,313 – +24% – £19,260,485 – £22,683,467 – -15%
South East Coast – 3,936,613 – 3,171,974 – +24% – £23,515,527 – £25,174,708 – -7%
South West – 5,439,577 – 4,298,164 – +26% – £26,425,152 – £29,940,081 – -12%
West Midlands – 4,854,135 – 3,890,459 – +25% – £26,751,239 – £29,522,750 – -9%
Yorkshire & Humber – 5,455,370 – 4,445,862 – +23% – £25,919,024 – £30,860,418 – -16%
Total – 49,864,399 – 39,556,255 – +26% – £258,360,117 – £291,583,854 – -12%

Guidance on how to be happy with yourself can be found at The Co-operative’s Magazine online, along with general nutrition advice and wellbeing advice.

Via EPR Network
More Healthcare press releases

Get beautiful with The Co-operative Magazine’s beauty videos online

The Co-operative Magazine’s resident fashion and beauty experts have recorded a series of brilliant “how to…” videos, aimed at women who want quick and easy ways to glam up for the festive party season.

The series includes, how to:
• …apply lipstick and lip liner
• …do gorgeous smokey eyes
• …apply professional false eyelashes
• …apply fake tan

It also includes a video guide to curling hair with straighteners for all those women who want to achieve gorgeous, professional-looking wavy locks to go with glamorous, new Christmas party outfits.

These five videos range from 90 seconds and six minutes in length, so it couldn’t be easier or quicker to get the beauty tips and tricks you need to look your best, even if you are short of time. Enjoy step-by-step practical tips on where to apply eyeliner and eye shadow for the perfect smokey look, how to hold hair straighteners to get the easiest curl, why to use a mitt when applying fake tan, and much more.

These beauty videos are perfect for those women who want help with perfecting their look, or who want to try something different for a special occasion. Watch them now online at The Co-operative Magazine, on your desktop PC, mobile phone or tablet and start experimenting with your look!

As well as great video content, The Co-operative Magazine also offers top fashion tips, shopping on a budget, moneysaving and budgeting, how to get fit and much more. Readers will find interesting and engaging topics on everything from travel and leisure to pets, motoring and healthy eating.

The December issue of the online Magazine is now available, and far from being just another Christmas-themed magazine, it gives great alternative meal ideas if you don’t fancy the usual turkey, stuffing and Brussels sprouts, as well as tips on how to have a healthy Christmas and stay out of debt.

Via EPR Network
More Healthcare press releases

Med-Q Introduces Tool to Reduce Medication Errors

When Lee DeMar was running a Phoenix-based nursing agency, he constantly heard his nurses voice their frustration over the fact that many of their older clients were not taking their medications when they should and as a result cycling back to the ER (the nurses worked exclusively at hospitals). Known as medication non-compliance (or non-adherence), it is the failure to take prescription medication on time and in the dosages prescribed.

Medication non-compliance — which has been called America’s “other drug problem” by The New York Times — results in an estimated $290 billion in emergency room visits and other avoidable medical expenses and health crises. These medication errors account for 10 percent of all hospital admissions, and is attributed to at least 125,000 deaths annually, according to the New England Healthcare Institute.

DeMar immediately recognized the urgency of this growing problem and through his company, Med-Q, developed the Med-Q Pillbox, an innovative solution to the challenges of medication non-compliance. The unit retails for $49.95 and is being launched at a special introductory price of $39.95.

Featuring a unique modern design, the Med-Q Pillbox is unlike any pill organizer on the market. It is a self-contained, “all-in-one” electronic weekly organizer, reminder and dispenser. According to DeMar, “The Med-Q Pillbox features a user-friendly design and multipurpose functionality to assist a wide range of individuals taking daily medications and vitamins.”

The Med-Q Pillbox consists of 14 days’ worth of roomy, individualized compartments to accommodate once a day (for 14 days) or twice a day (for 7 days) medication regimens. Each individual compartment is specially fitted with large flip-up tabs for easy opening and can hold the equivalent of up to 30 regular-size aspirins. Additionally, each compartment can be removed from the pillbox base eliminating the potential to spill pills from other compartments that may not be closed securely. An extra large LED makes it easier to program and see the day, time and “next alert.”

Med-Q’s electronic dual reminder system, according to DeMar “is a technology and design breakthrough for individuals and families trying to adhere to daily medication regimens and live a medically-independent life.”

Powered by two AA batteries, the Med-Q Pillbox combines advanced audio and visual alarms, and may be programmed to fit any schedule. The audio alarm, available in one- or two-beep options, cascades in volume and is loud enough to be heard through a nightstand drawer. The visual alarm utilizes LED-Lightbox Technology™ to illuminate individual compartments with a flashing light and indicates which pills to take.

The goal of the Med-Q Pillbox is to reduce medication errors. For more information or to purchase the Med-Q Pillbox, please visit www.medqpillbox.com or call 480-648-4977.

Via EPR Network
More Healthcare press releases

Great Ormond Street Hospital Supports Stem Cell Awareness Day

Great Ormond Street Hospital and its research partner, The Institute of Child Health at University College London (UCL), are supporting Stem Cell Awareness Day, with UCL promoting the event with the launch of a new YouTube video featuring Mr Paolo de Coppi and his colleagues.

Mr. de Coppi is Clinical Senior Lecturer in the Surgery Unit at The Institute of Child Health at UCL and carries out stem cell research at Great Ormond Street Hospital. It is hoped the research will result in stem cells being used to repair damaged organs. Mr de Coppi has looked for naturally occurring stem cells in amniotic fluid as a novel solution to some of the serious birth defects he sees. Around 40 per cent of patients at Great Ormond Street Hospital have some form of birth defect.

Mr de Coppi said: “As a surgeon I often see the devastating effects of multiple reconstructive operations aimed at replacing damaged organs. I have therefore focused my research interests on stem cells and tissue engineering, trying to find new ways to treat complex birth defects. I have identified stem cells in the amniotic fluid and found they have the ability to become many different types of cell. Our research aims to find ways of using these cells to repair and replace damaged tissues, so that babies are given the chance of a healthy life from the day they are born.

“The idea is we can create tissues in a test tube using a baby’s own cells, and then implant these at birth. We’re looking at repairing organs like intestines or windpipes. Grown from a child’s own cells, there should be no rejection of tissue.”

The video sees Mr. de Coppi discussing the work he and his colleagues carry out and offering insight into the latest developments relating to his stem cell research and the possibility of deriving cells from amniotic fluid. The full video can be viewed here: http://www.youtube.com/watch?v=qD_V1hqR6SI.

Via EPR Network
More Healthcare press releases

New York State Department of Health (NYSDOH) Cited for Non-Assistance to a New York Community in 9/11 Crisis

Charges of non-assistance to a New York community, post 9/11, in a context of bias and discrimination, were filed with the U.S. Health and Human Services (HHS), the Federal Emergency Management Administration (FEMA), and the New York State Division of Human Rights (NYSDHR).

According to the Verified Complaints, the New York State Department of Health (NYSDOH) ignored repeated requests to assist in the medical and mental health care of French-American residents of New York, and of French tourists trapped by the 9/11 cataclysm.

As official coordinator for the French consular 9/11 crisis task force, Gérard Sunnen, MD, a U.S. veteran and dual national, reported that many individuals were severely distraught and maximally stressed by the 9/11 catastrophe and needed acute and chronic support services. He pointed out that French president Jacques Chirac was the first president of a foreign nation to come to New York after 9/11, offering his nation’s condolences and assistance. After his visit, he promptly dispatched French senator Monique Cerisier-ben Guiga to New York to oversee consular humanitarian actions.

“The prejudicial actions of the NYSDOH then reached new heights in the era offreedom fries” as part of a pattern and in a spirit of retribution for France’s non-participation in the Iraq conflict. Curiously, nowhere did it ever reach the intensity of New York,” reports Dr. Sunnen, “please recall the well-publicized incidents of wine bottles vindictively smashed in the streets, the eggs thrown at the façade of the Consulate of France, and the inflammatory headlines in the New York tabloids during those times. Because of coordinated boycotts, many French-owned businesses failed in New York, creating widespread mental health calamities.”

“Consequences of NYSDOH’s usage of its powers traveled far beyond New York,” said Dr. Sunnen, adding, “We were working with our Egyptian colleagues on two clinical studies, under the auspices of the University of Cairo and the Egyptian Ministry of Health. Both studies aimed at major public health issues in the Middle East and in the U.S., one regarding hepatitis C in Egypt, where the hepatitis C prevalence is by far the highest in the world, and the other on diabetic skin ulcers, a major cause of lower leg amputations worldwide. “

“Due to NYSDOH’s interference, the research contracts fell through and the studies were abandoned.” Information on the impedance to these international medical research initiatives can be found on the Internet. Legislative attempts designed to curb NYSDOH’s oft-reported undemocratic practices were all vetoed by Governor George E. Pataki in 2004.

Dr. Sunnen concluded, “In countering today’s tendency for international polarizations, friends and allies need to solidify their ties and cooperative efforts, and there may be nowhere better to start than with actively nurturing medical fellowship and goodwill.”

Via EPR Network
More Healthcare press releases

The Co-operative Magazine Outlines Health Services for Ramadan

The Co-operative Magazine has this week published information on the healthcare services that are available at The Co-operative Pharmacy stores during the Muslim festival of Ramadan.

The Magazine gives its readers the chance to take advantage of the knowledge, expertise and experience of pharmacists at The Co-operative Pharmacy during this important religious festival. Readers are given more information on how to participate safely in Ramadan, Hajj and Umrah, and given details of the dedicated healthcare service for Muslims across the UK.

The article states that specially trained pharmacists will be working at 84 branches of The Co-operative Pharmacy, available to give specific advice and support on all aspects of observing the practices of Ramadan, Hajj and Umrah safely.

Specialist help will include guidance on how to manage regular, orally-administered medication during the period of fasting, as well as advice on how to stop smoking and what vaccinations are necessary for those preparing for Hajj. The Co-operative understands that Ramadan is a good time to beat addiction as those observing the practices of the festival are required to abstain completely from food and resist all temptations during daylight hours.

Business development director at The Co-operative, Mandeep Mudhar, said: “We appreciate the importance of cultural understanding and sensitivity when discussing the implications of healthcare on people’s religious beliefs. But our trained pharmacists are here to help with this and with the preparations leading up to Hajj or Umrah.”

Once Ramadan is over, The Co-operative Pharmacy will focus on giving the meningococcal vaccine, as well as specialist health advice for those making the pilgrimage to Mecca. The Co-operative Pharmacy will be working with Novartis Vaccines and The Muslim Council of Britain to offer meningococcal vaccination (ACWY) packages to Muslim pilgrims.

For more information, read The Co-operative Magazine or find your nearest branch of The Co-operative Pharmacy with the online store finder.

Via EPR Network
More Healthcare press releases